Even amid the challenges of 2020, I-ACT for Children achieved important progress in our efforts to accelerate and enhance the quality of pediatric clinical trials. We have highlighted these and other efforts in I-ACT for Children’s first Annual Report.

Join us on Oct. 16 from 10 am to 11 am to discuss remote patient monitoring and its role in preserving the continuity of pediatric clinical trials amid the COVID-19 pandemic and beyond. Co-hosted by I-ACT for Children and Aparito, the virtual discussion will feature researchers and regulators in the US, Canada and Europe discussing the importance of this innovation in maximizing access to and participation in pediatric trials.

The COVID-19 Emergency Access Program allows all biopharmaceutical and other companies developing COVID-19 treatments and vaccines to use the organization’s pediatric research network to conduct their pediatric trials.

Learn more about our Emergency Access Program by clicking here.

I-ACT for Children and Parent Project Muscular Dystrophy co-hosted a stakeholder meeting on Sept. 9, 2019, to seek input on a draft platform trial protocol that is designed to allow multiple investigational treatments for Duchenne muscular dystrophy to be tested at one time – which could lead to more rapid completion of testing and approval of new therapies and minimize patients’ exposure to placebo. FDA’s Dr. Janet Woodcock and Dr. Billy Dunn were featured speakers at the meeting, which also was attended by researchers, parents, advocacy groups, industry representatives and other FDA scientists.

I-ACT for Children hosted its 1st annual Pediatric Research Innovation Forum on Oct. 15-16, which focused on the inclusion of adolescents in adult clinical trials. The goal of the meeting was to drive innovation in this area by bringing key stakeholders together to agree on what’s known, identify continuing challenges and propose solutions to address those challenges.

I-ACT for Children is involved in a host of projects, both proprietary and in the pre-competitive space.